Pasar al contenido principal

Genomic and epigenomic characterization to unravel the molecular mechanisms underlying immune-mediated diseases

RYC2022-036635-I

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Desarrollar, Atraer y Retener Talento
Subprograma Subprograma Estatal de Incorporación
Convocatoria Ramón y Cajal
Año convocatoria 2022
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 5
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

A Strong Dysregulated Myeloid Component in the Epigenetic Landscape of Systemic Sclerosis: An Integrated DNA Methylome and Transcriptome Analysis, Genome‐wide integrated DNA methylome and transcriptome analysis reveals a strong dysregulated myeloid component in the epigenetic landscape of Systemic Sclerosis

  • Martínez-López, Javier
  • Ortiz-Fernández, Lourdes
  • Estupiñán-Moreno, Elkyn
  • Kerick, Martin
  • Andrés-León, Eduardo
  • Terrón-Camero, Laura Carmen
  • Carnero-Montoro, Elena
  • Barturen, Guillermo
  • Beretta, Lorenzo
  • Almeida, Isabel
  • Alarcón-Riquelme, M. E.
  • Ballestar, Estéban
  • Acosta-Herrera, Marialbert
  • Martín, Javier
This research is part of the doctoral degree awarded to Dr Martínez-L opezwithin the biomedicine program from the University of Granada., [Objective] Nongenetic factors influence systemic sclerosis (SSc) pathogenesis, underscoring epigenetics as a rel-evant contributor to the disease. We aimed to unravel DNA methylation abnormalities associated with SSc through anepigenome-wide association study., [Methods] We analyzed DNA methylation data from whole-blood samples in 179 patients with SSc and 241 unaffected individuals to identify differentially methylated positions (DMPs) with a false discovery rate (FDR) <0.05. Theseresults were further integrated with RNA sequencing data from the same patients to assess their functional conse-quence. Additionally, we examined the impact of DNA methylation changes on transcription factors and analyzed therelationship between alterations of the methylation and gene expression profile and serum proteins levels, [Results] This analysis yielded 525 DMPs enriched in immune-related pathways, with leukocyte cell–cell adhesionbeing the most significant (FDR = 4.91 × 10−9 ), prioritizing integrins as they were exposed by integrating methylomeand transcriptome data. Furthermore, through this integrative approach, we observed an enrichment of neutrophil-related pathways, highlighting this myeloid cell type as a relevant contributor in SSc pathogenesis. In addition, weuncovered novel profibrotic and proinflammatory mechanisms involved in the disease. Finally, the altered epigeneticand transcriptomic signature revealed an increased activity of CCAAT/enhancer-binding protein transcription factorfamily in SSc, which is crucial in the myeloid lineage developmen, [Conclusion] Our findings uncover the impaired epigenetic regulation of the disease and its impact on gene expres-sion, identifying new molecules for potential clinical applications and improving our understanding of SSc pathogenesis, We thank Sofia Vargas and Gema Robledo for their excellent technical assistance; all members of the PRECISESADS consortium, particularly Ralf Lesche, Sepideh Babaei, Anne Buttgereit, Suzana Makowska, and Martina Runge for preparing the RNA-seq data; and Johan Frostegård and Jacques-Olivier Pers for preparing and normalizing the serum protein data. We also want to thank all the patients and control donors for their essential collaboration., Supported by the Innovative Medicines Initiative Joint Undertaking (grant115565; PRECISESADS project), resources of which are composed of financialcontribution from the European Union’s Seventh Framework Program(FP7/2007–2013) and European Federation of Pharmaceutical Industries and Associations companies’ in-kind contribution, and by Redes de Investigacion Cooperativa Orientadas a Resultados en Salud through Instituto de SaludCarlos III (ISCIII) (RD21/0002/0039). Mr Martínez-Lopez’s work was supported by a predoctoral contract in health related research (PFIS) (FI23/00231) from ISCIII. Dr Ortiz-Fernandez’s work was supported by a Ramon y Cajal fellowship (RYC2022-036635-I) funded by MICIU/AEI/10.13039/501100011033 and by ESF+. Dr Acosta-Herrera’s work was supported by a Miguel Servet fellowship (CP21/00132) from ISCIII, Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Unraveling the molecular landscape of Erdheim-Chester disease: new insights from methylome and transcriptome integration

  • Cerván-Martín, Miriam
  • Pegoraro, Francesco
  • Martínez-López, Javier
  • Rodríguez-Martín, Inmaculada
  • Márquez, Ana
  • Ortiz-Fernández, Lourdes
  • Acosta-Herrera, Marialbert
  • Kerick, Martin
  • Andrés-León, Eduardo
  • Catamerò, Francesco
  • Papo, Matthias
  • Cohen-Aubart, Fleur
  • Amoura, Zahir
  • Haroche, Julien
  • Vaglio, Augusto
  • Martín, Javier
Erdheim-Chester Disease (ECD) is a rare histiocytosis characterized by a wide spectrum of clinical manifestations. Although somatic mutations have been involved in ECD, its etiology remains poorly understood. This study aimed to identify novel molecular mechanisms involved in ECD through the first integrated methylome and transcriptome analysis. Peripheral blood samples were collected from 137 ECD patients and 410 controls. Genome-wide DNA methylation and transcriptome analyses were performed, followed by functional in silico studies using different online bioinformatics tools. Subsequently, methylome and transcriptome data were integrated, and a drug repurposing approach was undertaken. Our results revealed 2511 differentially methylated positions and 1484 differentially expressed genes associated with ECD. The integrative analysis identified 46 alterations in DNA methylation patterns that regulate the expression levels of 29 altered genes in ECD patients, highlighting key genes involved in immune response and tumorigenesis. Remarkably, our results identified B cells and NF-kB signaling pathway as novel contributors of ECD pathogenesis. Finally, the drug repurposing analysis identified potential therapeutic options for ECD patients. In conclusion, this study represents an important advance in understanding the molecular basis of ECD, proposing novel cell types and pathways involved in ECD pathogenesis and suggesting new avenues for clinical management., This work was supported by the project “Genome-wide and epigenome-wide association study in patients with Erdheim-Chester Disease,” funded by Histio UK. M.C.-M is beneficiary of a Juan de la Cierva 2022 postdoctoral fellowship (reference number JDC2022-048561-I) funded by MCIN/AEI/ 10.13039/501100011033 and European Union NextGenerationEU/PRTR. J.M.L was supported by a predoctoral contract in health related research (PFIS) (FI23/00231) from ISCIII. I.R.M was supported by the program FPU (FPU21/02746) funded by the Spanish Ministry of Science Innovation and Universities. L.O.F. is recipient of a Ramon y Cajal fellowship [RYC2022-036635-I] funded by MICIU/AEI/10.13039/501100011033 and by ESF+., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Genome-Wide DNA Methylation Study Reveals Specific Signatures in the Affected Arterial Tissue of Patients With Giant Cell Arteritis

  • Borrego Yaniz, Gonzalo
  • Márquez, Ana
  • Estupiñán-Moreno, Elkyn
  • Terrón-Camero, Laura Carmen
  • González-Gay, Miguel A.
  • Castañeda, Santos
  • Guggino, Giuliana
  • Saadoun, David
  • Lio, Pietro
  • Fontana, Simona
  • Bonacini, Martina
  • Rossi, Alessandro
  • Cavazza, Alberto
  • Muratore, Francesco
  • Salvarani, Carlo
  • Pipitone, Nicolo
  • Rocha-Martín, Javier
  • Croci, Stefania
  • Ortiz-Fernández, Lourdes
This research is part of the doctoral degree awarded to Gonzalo Borrego-Yaniz, MSc, within the Biomedicine program from the University of Granada., [Objective] Giant cell arteritis (GCA) is a large-vessel vasculitis, potentially causing complications such as blindness and strokes. This study aims to gain insights into the pathogenesis of GCA by identifying specific DNA methylation signatures in the arterial tissue of patients with this vasculitis., [Methods] DNA methylation profiling was analyzed in 79 temporal artery biopsy samples (69 patients with GCA and 10 controls) by performing an epigenome-wide association study (EWAS). Differential analysis was performed to identify differentially methylated positions (DMPs) and differentially methylated regions (DMRs). Lastly, we compared our findings with previous transcriptomics and epigenomics studies on GCA-affected arteries., [Results] EWAS identified 3,644 DMPs (Padj < 0.05, |Δβ| > 0.3), indicating a profound alteration within GCA-affected arterial tissue. These DMPs were annotated to 1,517 potentially dysregulated genes. A total of 282 additional genes were identified by annotation of significant DMRs. Pathway enrichment analysis revealed a significant alteration of inflammatory mechanisms, such as interleukin-2 and interleukin-7, as well as pathways related to vascular remodeling. Omics study comparison revealed 37 genes consistently affected across datasets, many of them linked to immune signaling and T cell regulation. Notably, markers of exhausted T cells, including SLAMF6 and HAVCR2, were present among them., [Conclusion] Our study identified GCA-specific DNA methylation signatures in arterial tissue, revealing disrupted inflammatory and vascular pathways and suggesting the involvement of exhausted T cells in this condition. These findings offer new insights into GCA pathogenesis and provide new potential targets for the treatment of this debilitating disease., Supported by a research grant from FOREUM Foundation for Research in Rheumatology. Dr Borrego-Yaniz's contract is part of the grant PREP2022-000712, funded by the MCIN/AEI/10.13039/501100011033 and the ESF+. Dr Ortiz-Fernández's work is supported by a Ramon y Cajal fellowship (RYC2022-036635-I) funded by MICIU/AEI/10.13039/501100011033 and by ESF+. Drs Martin, Croci, and Ortiz-Fernández contributed equally to this work., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Novel pleiotropic loci link vascular and immune pathways in systemic sclerosis and primary Raynaud's phenomenon

  • Rangel-Peláez, Carlos
  • Rodríguez-Martín, Inmaculada
  • Rosa Baez, Carlos de la
  • Kerick, Martin
  • Guillén del Castillo, Alfredo
  • Simeón, Carmen P.
  • Callejas-Rubio, José Luis
  • Distler, Oliver
  • Proudman, Susanna
  • Nikpour, Mandana
  • Hunzelmann, Nicolas
  • Moroncini, Gianluca
  • Vries-Bouwstra, Jeska K. de
  • Herrick, A.
  • Allanore, Yannick
  • Alarcón-Riquelme, M. E.
  • Beretta, Lorenzo
  • Mayes, Maureen D.
  • Denton, Christopher
  • Assassi, Shervin
  • Martín, Javier
  • Acosta-Herrera, Marialbert
  • Ortiz-Fernández, Lourdes
  • International SSc Group
  • PRECISESADS Clinical Consortium
  • Australian Scleroderma Interest Group (ASIG)
[Objective] Raynaud’s phenomenon (RP) is the first noticeable symptom of systemic sclerosis (SSc), appearing even years before other signs. Vascular and immune pathways, hallmarks in SSc pathogenesis, are implicated in primary RP. Hence, we aimed to define the shared genetic architecture between these conditions to explore pathogenic mechanisms and whether pleiotropic loci could help identify primary RP patients at increased genetic risk of developing SSc., [Methods] We analysed genome-wide association study (GWAS) summary statistics for primary RP (4 986 cases and 850 981 controls) and SSc (10 654 cases and 18 043 controls). We performed a cross-trait meta-analysis (∼8.6M single nucleotide polymorphisms) to identify variants associated with both diseases. Functional annotation was used to prioritise potential causal genes. We also constructed a polygenic risk score (PRS) to assess clinical implications., [Results] Beyond the well-known HLA associations, we identified five additional pleiotropic loci, including MEOX2 as a novel association for both traits with opposing effects, ADRA2A representing a novel genetic factor for SSc, and IL12A, NFKB1 and TNIP1 as novel loci for primary RP. Functional annotation highlighted vascular and inflammatory pathways. Finally, the PRS model shows modest discrimination (area under the curve = 0.57). However, it allows the identification of primary RP individuals at high genetic risk of developing SSc (75th percentile, relative risk =1.29 [95% CI 1.02, 1.62]; P-value= 3.58 × 10−2)., [Conclusion] This study reveals a genetic link between primary RP and SSc, identifying five novel pleiotropic loci and supporting the potential of genetic profiling for early risk assessment and personalised monitoring strategies., This work was supported by Cooperative Research Networks Oriented to Health Results (RICORS), Inflammatory Diseases Network (REI) (RD21/0002/0039; RD24/0007/0016) from Carlos III Health Institute (ISCIII); grant PID2022-139292OB-I00 funded by MICIU/AEI/10.13039/501100011033 and by FSE+; and by the Innovative Medicines Initiative Joint Undertaking (grant 115565; PRECISESADS project), resources of which are composed of financial contribution from the European Union’s Seventh Framework Program (FP7/2007–2013) and European Federation of Pharmaceutical Industries and Associations companies’ in-kind contribution. This research was also supported by the National Institute for Health and Care Research (NIHR) Manchester Biomedical Research Centre (NIHR203308). The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care. L.O.-F. is recipient of a Ramon y Cajal fellowship [RYC2022-036635-I] funded by MICIU/AEI/10.13039/501100011033 and by ESF+. C.R.-B. was supported by the program FPU: [FPU22/01652], funded by the Spanish Ministry of Science Innovation and Universities. I.R.-M. was supported by the program FPU: [FPU21/02746], funded by the Spanish Ministry of University. C.R.-P. was funded by Grant PREP2022-000747 funded by MICIU/AEI/10.13039/501100011033 and by ESF+., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Sex-specific autosomal susceptibility loci in systemic sclerosis: a genome-wide association study

  • Rodríguez-Martín, Inmaculada
  • Kerick, Martin
  • Rangel-Peláez, Carlos
  • Rosa-Baez, Carlos
  • Borrego Yaniz, Gonzalo
  • Ortiz-Fernández, Lourdes
  • Guillén del Castillo, Alfredo
  • Simeón-Aznar, Carmen P.
  • Callejas-Rubio, José Luis
  • Distler, Oliver
  • Proudman, Susanna
  • Nikpour, Mandana
  • Hunzelmann, Nicolas
  • Vries-Bouwstra, Jeska K. de
  • Herrick, A.
  • Allanore, Yannick
  • Alarcón-Riquelme, M. E.
  • Beretta, Lorenzo
  • Assassi, Shervin
  • Denton, Christopher
  • Mayes, Maureen D.
  • Martín, Javier
  • Acosta-Herrera, Marialbert
  • International SSc Group
  • PRECISESADS Clinical Consortium
  • Australian Scleroderma Interest Group (ASIG)
International SSc Group: P. Carreira, I. Castellvi, R. Ríos, N. Ortego-Centeno, R. García Portales, A. Fernández-Nebro, F.J. García-Hernández, M.A. Aguirre, B. Fernández-Gutiérrez, L. Rodríguez-Rodríguez, P. García de la Peña, E. Vicente, J.L. Andreu, M. Fernández de Castro, F.J. López-Longo, V. Fonollosa, A. Guillén, G. Espinosa, C. Tolosa, A. Pros, E. Beltrán, M. Rodríguez Carballeira, F.J. Narváez, M. Rubio Rivas, V. Ortiz-Santamaría, A.B. Madroñero, M.A. González-Gay, B. Díaz, L. Trapiella, M.V. Egurbide, P. Fanlo-Mateo, L. Saez-Comet, F. Díaz, J.A. Roman-Ivorra, J.J. Alegre Sancho, M. Freire, F.J. Blanco Garcia, N. Oreiro, T. Witte, A. Kreuter, G. Riemekasten, P. Airo, C. Magro, A.E. Voskuyl, M.C. Vonk, R. Hesselstrand, A. Nordin, C. Lunardi, G. Moroncini, A. Gabrielli, A. Hoffmann-Vold, J.H.W. Distler, L. Padyukov, B.P.C. Koeleman, T.R.D.J. Radstake, G. Orozco, A. Barton, C. Fonseca, The PRECISESADS Clinical Consortium: Barbara Vigone, Jacques-Olivier Pers, Alain Saraux, Valérie Devauchelle-Pensec, Divi Cornec, Sandrine Jousse-Joulin, Bernard Lauwerys, Julie Ducreux, Anne-Lise Maudoux, Carlos Vasconcelos, Ana Tavares, Esmeralda Neves, Raquel Faria, Mariana Brandão, Ana Campar, António Marinho, Fátima Farinha, Miguel Angel Gonzalez-Gay Mantecón, Ricardo Blanco Alonso, Alfonso Corrales Martínez, Ricard Cervera, Ignasi Rodríguez-Pintó, Gerard Espinosa, Rik Lories, Ellen De Langhe, Nicolas Hunzelmann, Doreen Belz, Torsten Witte, Niklas Baerlecken, Georg Stummvoll, Michael Zauner, Michaela Lehner, Eduardo Collantes, Rafaela Ortega-Castro, M Angeles Aguirre-Zamorano, Alejandro Escudero-Contreras, M Carmen Castro-Villegas, Norberto Ortego, María Concepción Fernández Roldán, Enrique Raya, Inmaculada Jiménez Moleón, Enrique de Ramon, Isabel Díaz Quintero, Pier Luigi Meroni, Maria Gerosa, Tommaso Schioppo, Carolina Artusi, Carlo Chizzolini, Aleksandra Zuber, Donatienne Wynar, Laszló Kovács, Attila Balog, Magdolna Deák, Márta Bocskai, Sonja Dulic, Gabriella Kádár, Falk Hiepe, Velia Gerl, Silvia Thiel, Manuel Rodriguez Maresca, Antonio López-Berrio, Rocío Aguilar-Quesada, Héctor Navarro-Linares, Australian Scleroderma Interest Group: A. Apostolopoulos, N. Ferdowsi, D. Hansen, L.V. Host, G. Major, G.-S. Ngian, A. Quinlivan, L. Ross, J. Sahhar, W. Stevens, M. Tabesh, J. Walker, [Background] Systemic sclerosis is an immune-mediated inflammatory disease with marked sex differences in prevalence and severity. Although genome-wide association studies (GWAS) have advanced the understanding of systemic sclerosis genetics, sex-aware approaches remain scarce. We aimed to address this gap by examining autosomal sex-specific genetic factors in systemic sclerosis., [Methods] Based on a chromosomal definition of sex, we conducted a sex-stratified autosomal meta-analysis of GWAS in systemic sclerosis. We retrieved patient-level and control data from a previous GWAS for systemic sclerosis and newly recruited participants from an international multicentre collaboration (data cutoff June 1, 2024). Adult patients (aged ≥18 years) were required to meet the 2013 American College of Rheumatology–European League Against Rheumatism classification criteria or the criteria for early systemic sclerosis proposed by LeRoy and Medsger, 2001. Patients with systemic sclerosis were compared with healthy controls through sex-stratified analyses. Sex-specific loci were functionally annotated and a sex-differential expression analysis was performed to validate the findings. Additionally, we performed a drug repurposing analysis to explore the clinical implications of our findings. People with lived experience of systemic sclerosis were not involved in the study design or conduct., [Findings] After quality control filtering, we included 10 653 patients with systemic sclerosis (1556 male and 9097 female) and 18 043 controls (6990 male and 11 053 female). We identified eight sex-specific loci associated with systemic sclerosis: one novel male-specific locus (BCL11A odds ratio [OR] 1·32 [95% CI 1·20–1·45], p=8·39 × 10–9), two novel female-specific loci (IRF4 OR 0·78 [0·71–0·85], p=2·36 × 10–8 RPL3-PDGFB OR 1·19 [1·12–1·26], p=3·18 × 10–8), and five previously known loci now characterised as female-specific. Functional analyses implicated 39 candidate genes, of which five (IL12RB2, ARHGAP31, UBL7, CSK, and MPI) showed sex-differential expression in patients with systemic sclerosis. Two approved drugs, fostamatinib and dasatinib, were identified as potential repurposing candidates for systemic sclerosis sex-aware treatment., [Interpretation] We report the first evidence of sex-specific genetic architecture in systemic sclerosis. These findings offer insight into the molecular basis of sex differences in the disease, highlighting both IL12RB2 gene and interferon signalling. These results also support the development of sex-aware precision medicine approaches., This work was supported by the Instituto de Salud Carlos III (CP21/00132, PI22/00092 [co-financed by the EU], and Redes de Investigación Cooperativa Orientadas a Resultados en Salud [RD21/0002/0039 and RD24/0007/0016]) and the Innovative Medicines Initiative Joint Undertaking (grant 115565; PRECISESADS project; these resources comprise financial contribution from the EU's Seventh Framework Program [FP7/2007–2013] and European Federation of Pharmaceutical Industries and Associations companies' in-kind contribution). IR-M (FPU21/02746) and CR-B (FPU22/01652) were supported by the programme Formación de Profesorado Universitario funded by the Spanish Ministry of Science, Innovation, and Universities (MICIU). CR-P was supported by grant PREP2022-000747 funded by MICIU/AEI/10.13039/501100011033 and by the European Social Fund Plus (ESF+). GB-Y's contract is part of the grant PREP2022-000712 funded by MICIU/AEI/10.13039/501100011033 and by ESF+. LO-F is a recipient of a Ramon y Cajal fellowship (RYC2022-036635-I) funded by MICIU/AEI/10.13039/501100011033 and by ESF+. The research was also supported by the UK National Institute for Health and Care Research (NIHR)Manchester Clinical Research Facility (NIHR203956). The views expressed are our own and not necessarily those of the NIHR or the UK Department of Health and Social Care. We thank Sofia Vargas and Gema Robledo for their exceptional technical expertise. We also thank all of the participants who provided the data for their essential collaboration and all members of the PRECISESADS consortium. During the preparation of this work we used ChatGPT (GPT 4) to enhance the writing of some sections of the manuscript. After using this tool, we reviewed and edited the content as needed and take full responsibility for the content of the published article. This research is part of the doctoral degree awarded to IR-M within the Biomedicine programme from the University of Granada., Instituto de Salud Carlos III, EU's Seventh Framework Program, and European Federation of Pharmaceutical Industries and Associations companies., Peer reviewed